Congressional Approval Of PATH Act Would Show U.S. Commitment To Addressing Antimicrobial Resistance

The Hill: World leaders take notice, clock is ticking on antibiotics
William G. Powderly, president of the Infectious Diseases Society of America

“Earlier this fall, the United Nations General Assembly met to declare a commitment to addressing the public health crisis of antimicrobial resistance. World leaders recognized that nations must act quickly and aggressively to combat drug-resistance and spur antibiotic research and development. The U.S. Senate can make an immediate and important contribution to this effort by passing the bipartisan Promise for Antibiotics and Therapeutics for Health (PATH) Act. … The PATH Act … would establish a new limited population approval pathway at the FDA for antibiotics that treat often life-threatening infections for which there exists an unmet medical need. … [A]ntimicrobial resistance must be treated with a sense of urgency. … Congressional approval of the PATH Act prior to adjourning for the year would demonstrate recognition that lives are on the line and that our nation is capable of exercising leadership to address the crisis” (11/8).